Durata Investor Sues To Halt $675M Actavis Deal
A Durata Therapeutics Inc. investor lodged a proposed class action aiming to block Actavis PLC's $675 million buyout of the infectious disease drugmaker, saying the offer shortchanges shareholders just as the...To view the full article, register now.
Already a subscriber? Click here to view full article